Analysis of Counterfeit Antidiabetic Drugs by UHPLC with the Agilent 1220 Infinity Mobile LC

Total Page:16

File Type:pdf, Size:1020Kb

Analysis of Counterfeit Antidiabetic Drugs by UHPLC with the Agilent 1220 Infinity Mobile LC Analysis of Counterfeit Antidiabetic Drugs by UHPLC with the Agilent 1220 Infinity Mobile LC Application Note Small Molecule Pharmaceuticals & Generics Author Abstract Sonja Schneider Counterfeiting in the pharmaceutical industry has become a serious and Agilent Technologies, Inc. underreported problem, particularly in developing countries. This Application Waldbronn, Germany Note shows the analysis of antidiabetic drugs of the sulfonylurea class using the Agilent 1220 Infinity Gradient LC system with diode array detector (DAD). Both HPLC and UHPLC methods revealed excellent precision, accuracy and linearity as well as comparable limits of detection and quantification. With retention time and spectral confirmation, chemical antidiabetic substances could be identified and quantified in antidiabetic drugs and dietary supplements. mAU 200 TCM drug 1 175 150 TCM drug 2 125 100 OTC diabetic drug 75 50 Standards 25 0 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 min Introduction O O O S The production of counterfeit drugs is a O O O NH O huge problem in developing countries, H especially in parts of Africa and Asia1, HH H where approximately 50% of all sold drugs are fake. According to the Food and Glipizide Gliclazide Drug Administration (FDA), counterfeit drugs comprise approximately 10% of the global medicine market. Counterfeiting O O O is found in both branded and generic H3C O O O O drugs, containing the wrong amount or HH 2 the wrong active ingredient . Chemical O drugs can be found in adulterated dietary H HH supplements, where no chemical active H ingredient is allowed. Cl GlibenclamideGlimepiride This Application Note shows the analysis of six antidiabetic drugs of the sulfonylurea class using the 1220 O Infinity Gradient LC system with DAD. O O O Figure 1 displays the six sulfonylurea O OH drugs: glipizide, gliclazide, glibenclamide, O HH glimepiride, gliquidone, and repaglinide. H These sulfonylurea drugs are commonly used in clinics to treat type II diabetes mellitus patients. The drugs stimulate Gliquidone Repaglinide the pancreas to release insulin, which Figure 1. Chemical antidiabetic drug substances of the sulfonylurea class. lowers blood sugar. Approximately 90% of diabetes patients suffer from type II diabetes, which represents noninsulin dependent diabetes mellitus2. The analysis of type II antidiabetes drugs is very important to ensure their safety and efficacy. The 1220 Infinity Gradient LC system with DAD enables the analysis of potentially counterfeit and adulterated antidiabetic drugs and dietary supplements to quantify and identify the active chemical ingredients. The Agilent 1220 Infinity Mobile LC Solution is a robust and rugged system for on-site measurement because it is resistant against shocks or vibrations during transportation. The 1220 Infinity Mobile LC Solution can be used in a mobile laboratory as for on-site drug analysis. 2 Experimental Software Results and Discussion The Agilent 1220 Infinity Gradient • Agilent OpenLAB CDS The antidiabetic drug standards were LC system with DAD (G4294B) was ChemStation Edition for LC & LC analyzed under HPLC conditions equipped with a dual gradient pump MS Systems, Rev. C.01.04 [35] according to Yao et al.2, see Figure 2. Six with integrated degasser, autosampler, consecutive runs were analyzed for their column compartment, and the diode array • Agilent OpenLAB CDS 3D UV precision regarding retention time and detector. For transportation, the LC can be Add-On software area. The relative standards deviation mounted on a transportation plate, 1220 (RSD) of retention time and area was Infinity Mobile Upgrade Kit (G4292A). found to be excellent, below 0.04% and 0.22% respectively. Sample Antidiabetics standards of glipizide, Chromatographic Conditions gliclazide, glibenclamide, glimepiride, and repaglinide and the excipients 4.6 × 150 mm, 5 µm 3 × 50 mm, 1.8 µm silica, starch, soluble, talc, magnesium stearate, cellulose, polyvinylpyrrolidone, Solvent Methanol:10 mM phosphate buffer, Methanol:10 mM phosphate buffer, pH 3 (70:30) pH 3 (65:35) and hypromellose were purchased from Sigma-Aldrich, St. Louis, MO, Flow rate 1 mL/min 1.5 mL/min USA. Gliquidone was purchased from Isocratic Stop time – 25 minutes Stop time – 2 minutes LGC Standards, Teddington, UK. The Injection volume 10 µL 1.4 µL antidiabetic drug and the dietary Temperature TCC RT 60 °C supplements were obtained through DAD 230 nm/16 nm Ref.: off 230 nm/16 nm Ref.: off online pharmacies in China. Peak width > 0.025 minutes 0.0063 minutes (0.5 second response time) (10 Hz) (0.13 second response time) (40 Hz) Stock solutions of antidiabetics were prepared at a concentration of 1 mg/mL in methanol. The standard solutions of 100 µg/mL were prepared from the mAU 2 No. Analyte% RSD RT % RSD area stock solutions. The excipient mixture 500 and the samples were filtered using 1Glipizide 0.0060.149 Agilent Captiva Premium Syringe Filter, 2Gliclazide0.006 0.219 3Glibenclamide 0.0240.115 regenerated cellulose membrane, 400 4Glimepiride 0.0260.153 15 mm diameter, 0.45 µm pore size 5Gliquidone0.038 0.150 (p/n 5190-5109). 300 6Repaglinide 0.0220.152 All solvents were LC grade. Fresh 1 ultrapure water was obtained from a 200 Milli-Q Integral system equipped with a 3 5 0.22 μm membrane point-of-use cartridge 4 (Millipak). 100 6 Columns 0 • Agilent ZORBAX Eclipse Plus C18 4.6 × 150 mm, 5 µm 2.5 5 7.5 10 12.5 15 17.5 20 min (p/n 959993-902) Figure 2. Six consecutive runs of six antidiabetic drug standards on an Agilent ZORBAX Eclipse Plus C18, 4.6 × 150 mm, 5 µm. • Agilent ZORBAX RRHD Eclipse Plus C18, 3 × 50 mm, 1.8 µm (p/n 959757-302) 3 To shorten the analysis time of the six No. Analyte% RSD RT % RSD area antidiabetic drug standards, the method 1Glipizide 0.034 0.450 mAU 1 was transferred to an UHPLC method 2Gliclazide 0.034 0.459 using an Agilent ZORBAX RRHD Eclipse 250 3Glibenclamide 0.027 0.568 Plus C18, 3 × 50 mm, 1.8 µm column. In 4Glimepiride 0.034 0.697 comparison to a 4.6-mm id column, it was 2 3 5Gliquidone 0.034 0.658 also possible to save solvent (over 85% 200 6Repaglinide 0.028 0.626 per analysis) using lower flow rates with the 3-mm column, but gaining the same 150 results. Figure 3 displays the UHPLC 5 analysis together with the precision results for retention time and area. 100 4 The RSD of retention time and area was 6 found to be below 0.04% respectively 50 0.7% for six consecutive runs. Regarding the over 10x shortening of the analysis 0 time, the RSDs of the UHPLC method 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 min were still excellent. Figure 3. Six consecutive runs of six antidiabetic drugs standards using an Agilent ZORBAX RRHD Eclipse Both methods were evaluated regarding Plus C18, 3 × 50 mm, 1.8 µm. linearity and limit of detection (LOD) and limit of quantitation (LOQ). Seven different concentration levels (from 100 µg/mL down to 0.14 µg/mL, 1:3 Table 1. Linearity and LOD/LOQ, a comparison between HPLC and UHPLC conditions. dilution) were prepared from the stock HPLC UHPLC HPLC LOD UHPLC LOD HPLC LOQ UHPLC LOQ solutions and the linear relationship was Analyte R² R² (pg) (pg) (pg) (pg) determined between the peak area and Glipizide 1 0.9999 66 38 221 127 the corresponding concentrations. LOD Gliclazide 1 0.9999 76 46 254 153 and LOQ were defined as the signal-to- noise ratio of 3:1 respectively 10:1. Table 1 Glibenclamide 1 0.9999 96 44 319 148 shows the results of the evaluation. Glimepiride 1 0.9999 121 80 403 268 Both methods showed very high linearity Gliquidone 1 0.9999 147 67 490 222 with coefficients of determination (R²) of Repaglinide 1 0.9999 469 214 1563 714 0.9999 for UHPLC and 1 for HPLC. LOD and LOQ were improved using the UHPLC conditions, double, for example, for glibenclamide. Table 2. Interference of seven tested excipients. Both methods were examined for Excipient Interference interference of seven of the most Silica - common excipients. Due to the Starch, soluble - hydrophilic properties of the excipient Talc - substances, resulting in a very early Magnesium stearate - elution, none of the excipients showed Cellulose - any interference (see Table 2). Polyvinylpyrrolidone - Hypromellose - 4 Both HPLC and UHPLC methods were HPLC and UHPLC method. Accuracy (TCM drug 1, TCM drug 2) were analyzed evaluated for their precision and accuracy was comparable between the HPLC and for the content of chemical antidiabetic regarding the calculated amount of the UHPLC method. Due to the shortening of drug substance. Figure 4 shows the six antidiabetic drug substances. For this the UHPLC method, the intra and interday chromatograms obtained from the experiment, 50 µg/µL per antidiabetic precision was slightly better for the HPLC samples compared to the standard substance was spiked into an excipient method. However, excellent precision mixture. The asterisks mark peaks, mixture, dissolved in methanol. Three was gained with both methods. resulting from the other ingredients of the replicates were analyzed on three capsules (main ingredient: bitter melon consecutive days to determine the One antidiabetic over-the-counter and other natural ingredients). accuracy as well as the intra and interday (OTC) drug sample (OTC diabetic precision. Table 3 displays the comparison drug) and two dietary supplements of accuracy and precision between the from traditional Chinese medicine Table 3. Precision and accuracy amount - HPLC versus UHPLC. HPLC UHPLC HPLC UHPLC Spiked HPLC UHPLC intraday intraday interday interday concentration accuracy accuracy precision precision precision precision Analyte (µg/mL) (%) (%) (%) (%) (%) (%) Glipizide 50 102.35 99.83 0.13 0.73 0.17 0.83 Gliclacide 50 99.09 100.79 0.04 1.13 0.75 1.24 Glibenclamide 50 98.35 101.55 0.03 0.85 0.21 0.94 Glimepiride 50 96.84 101.61 0.05 0.26 0.42 0.81 Gliquidone 50 98.79 100.20 0.07 0.32 0.42 0.92 Repaglinide 50 97.97 104.56 0.11 0.15 0.49 0.97 mAU * 3 200 TCM drug 1 175 * 150 3 TCM drug 2 125 2 100 OTC diabetic drug 75 1 50 2 3 5 Standard mixture 25 4 6 0 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 min Figure 4.
Recommended publications
  • PRANDIN® (Repaglinide) Tablets (0.5, 1, and 2 Mg) Rx Only
    PRANDIN® (repaglinide) Tablets (0.5, 1, and 2 mg) Rx only DESCRIPTION PRANDIN® (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide, S(+)2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)- butyl) amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea insulin secretagogues. The structural formula is as shown below: CH3 O OH H3C O N O H N CH3 Repaglinide is a white to off-white powder with molecular formula C27 H36 N2 O4 and a molecular weight of 452.6. PRANDIN tablets contain 0.5 mg, 1 mg, or 2 mg of repaglinide. In addition each tablet contains the following inactive ingredients: calcium hydrogen phosphate (anhydrous), microcrystalline cellulose, maize starch, polacrilin potassium, povidone, glycerol (85%), magnesium stearate, meglumine, and poloxamer. The 1 mg and 2 mg tablets contain iron oxides (yellow and red, respectively) as coloring agents. CLINICAL PHARMACOLOGY Mechanism of Action Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta (ß) cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations. Repaglinide closes ATP-dependent potassium channels in the ß-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the ß-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.
    [Show full text]
  • Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes
    Oral Health Fact Sheet for Dental Professionals Adults with Type 2 Diabetes Type 2 Diabetes ranges from predominantly insulin resistant with relative insulin deficiency to predominantly an insulin secretory defect with insulin resistance, American Diabetes Association, 2010. (ICD 9 code 250.0) Prevalence • 23.6 million Americans have diabetes – 7.8% of U.S. population. Of these, 5.7 million do not know they have the disease. • 1.6 million people ≥20 years of age are diagnosed with diabetes annually. • 90–95% of diabetic patients have Type 2 Diabetes. Manifestations Clinical of untreated diabetes • High blood glucose level • Excessive thirst • Frequent urination • Weight loss • Fatigue Oral • Increased risk of dental caries due to salivary hypofunction • Accelerated tooth eruption with increasing age • Gingivitis with high risk of periodontal disease (poor control increases risk) • Salivary gland dysfunction leading to xerostomia • Impaired or delayed wound healing • Taste dysfunction • Oral candidiasis • Higher incidence of lichen planus Other Potential Disorders/Concerns • Ketoacidosis, kidney failure, gastroparesis, diabetic neuropathy and retinopathy • Poor circulation, increased occurrence of infections, and coronary heart disease Management Medication The list of medications below are intended to serve only as a guide to facilitate the dental professional’s understanding of medications that can be used for Type 2 Diabetes. Medical protocols can vary for individuals with Type 2 Diabetes from few to multiple medications. ACTION TYPE BRAND NAME/GENERIC SIDE EFFECTS Enhance insulin Sulfonylureas Glipizide (Glucotrol) Angioedema secretion Glyburide (DiaBeta, Fluconazoles may increase the Glynase, Micronase) hypoglycemic effect of glipizide Glimepiride (Amaryl) and glyburide. Tolazamide (Tolinase, Corticosteroids may produce Diabinese, Orinase) hyperglycemia. Floxin and other fluoroquinolones may increase the hypoglycemic effect of sulfonylureas.
    [Show full text]
  • Package Leaflet: Information for the User
    Package leaflet: Information for the patient [Repaglinide] 0.5 mg tablets [Repaglinide] 1.0 mg tablets [Repaglinide] 2.0 mg tablets repaglinide Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What [Repaglinide] is and what it is used for 2. What you need to know before you take [Repaglinide] 3. How to take [Repaglinide] 4. Possible side effects 5. How to store [Repaglinide] 6. Contents of the pack and other information 1. What [Repaglinide] is and what it is used for [Repaglinide] is an oral antidiabetic agent containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose). Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces (formerly known as non-insulin-dependent diabetes mellitus or maturity onset diabetes). [Repaglinide] is used to control type 2 diabetes as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,026,285 B2 Bezwada (45) Date of Patent: Sep
    US008O26285B2 (12) United States Patent (10) Patent No.: US 8,026,285 B2 BeZWada (45) Date of Patent: Sep. 27, 2011 (54) CONTROL RELEASE OF BIOLOGICALLY 6,955,827 B2 10/2005 Barabolak ACTIVE COMPOUNDS FROM 2002/0028229 A1 3/2002 Lezdey 2002fO169275 A1 11/2002 Matsuda MULT-ARMED OLGOMERS 2003/O158598 A1 8, 2003 Ashton et al. 2003/0216307 A1 11/2003 Kohn (75) Inventor: Rao S. Bezwada, Hillsborough, NJ (US) 2003/0232091 A1 12/2003 Shefer 2004/0096476 A1 5, 2004 Uhrich (73) Assignee: Bezwada Biomedical, LLC, 2004/01 17007 A1 6/2004 Whitbourne 2004/O185250 A1 9, 2004 John Hillsborough, NJ (US) 2005/0048121 A1 3, 2005 East 2005/OO74493 A1 4/2005 Mehta (*) Notice: Subject to any disclaimer, the term of this 2005/OO953OO A1 5/2005 Wynn patent is extended or adjusted under 35 2005, 0112171 A1 5/2005 Tang U.S.C. 154(b) by 423 days. 2005/O152958 A1 7/2005 Cordes 2005/0238689 A1 10/2005 Carpenter 2006, OO13851 A1 1/2006 Giroux (21) Appl. No.: 12/203,761 2006/0091034 A1 5, 2006 Scalzo 2006/0172983 A1 8, 2006 Bezwada (22) Filed: Sep. 3, 2008 2006,0188547 A1 8, 2006 Bezwada 2007,025 1831 A1 11/2007 Kaczur (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2009/0076174 A1 Mar. 19, 2009 EP OO99.177 1, 1984 EP 146.0089 9, 2004 Related U.S. Application Data WO WO9638528 12/1996 WO WO 2004/008101 1, 2004 (60) Provisional application No. 60/969,787, filed on Sep. WO WO 2006/052790 5, 2006 4, 2007.
    [Show full text]
  • 9567-Sandoz Repaglinide Product Monograph.Pdf
    PRODUCT MONOGRAPH PrSANDOZ REPAGLINIDE (Repaglinide) 0.5 mg, 1 mg and 2 mg tablets Oral Antidiabetic Agent Manufacturer's Standard Sandoz Canada Inc. Date of Revision: 110 de Lauzon August 16, 2018 Boucherville, QC J4B 1E6 Submission Control No: 218326 Sandoz Repaglinide Page 1 of 43 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 7 DRUG INTERACTIONS ................................................................................................. 11 DOSAGE AND ADMINISTRATION ............................................................................. 16 OVERDOSAGE ............................................................................................................... 17 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 18 STORAGE AND STABILITY ......................................................................................... 21 DOSAGE FORMS, COMPOSITION AND PACKAGING
    [Show full text]
  • PRANDIN (Repaglinide) Tablets (0.5, 1, and 2
    PRANDIN® (repaglinide) Tablets (0.5, 1, and 2 mg) Rx only DESCRIPTION PRANDIN® (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide, S(+)2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)­ butyl) amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea insulin secretagogues. The structural formula is as shown below: CH3 O OH 3CH O N O H N CH3 Repaglinide is a white to off-white powder with molecular formula C27 H36 N2 O4 and a molecular weight of 452.6. PRANDIN tablets contain 0.5 mg, 1 mg, or 2 mg of repaglinide. In addition each tablet contains the following inactive ingredients: calcium hydrogen phosphate (anhydrous), microcrystalline cellulose, maize starch, polacrilin potassium, povidone, glycerol (85%), magnesium stearate, meglumine, and poloxamer. The 1 mg and 2 mg tablets contain iron oxides (yellow and red, respectively) as coloring agents. CLINICAL PHARMACOLOGY Mechanism of Action Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta (ß) cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations. Repaglinide closes ATP-dependent potassium channels in the ß-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the ß-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.
    [Show full text]
  • The Role of Nateglinide and Repaglinide, Derivatives of Meglitinide, in the Treatment of Type 2 Diabetes Mellitus
    State of the art paper The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus Rodolfo Guardado-Mendoza 1, Annamaria Prioletta 2 , Lilia M. Jiménez-Ceja 1, Aravind Sosale 3, Franco Folli 4 1Department of Medicine and Nutrition, Division of Health Sciences, University Corresponding author: of Guanajuato, México Franco Folli MD, PhD 2Diabetes Center, ACISMOM Associazione Cavalieri Italiani Sovrano Militare Ordine University of Texas Health Di Malta, Italy Science Center 3Diacon Hospital, Bangalore, India Department of Medicine 4Department of Medicine, Diabetes Division, University of Texas Health Science Center Diabetes Division at San Antonio, Texas, USA Mail Stop 7886–7703 Floyd Curl Drive-San Antonio Submitted: 13 November 2012 TX 78229-3900, USA Accepted: 31 January 2013 Phone: 210-567-4826. E-mail: [email protected] Arch Med Sci 2013; 9, 5: 936–943 DOI: 10.5114/aoms.2013.34991 Copyright © 2013 Termedia & Banach Abstract Type 2 diabetes mellitus (T2DM) is one of the most common chronic diseases worldwide, presenting a great challenge to the public health systems due to high morbidity and mortality, because of frequent micro-/macro-vascular com - plications. Many treatment options are now available, with different efficacy as well as mechanisms of action to improve deranged glucose metabolism. We review some of the available data on derivatives of meglitinide, namely nateglin - ide and repaglinide. These two compounds increase insulin secretion by a mech - anism similar to the one of sulfonylureas, but with a shorter half-life. Nateglinide and repaglinide, derivatives of meglitinides, have characteristic pharmacody - namic and pharmacokinetic properties that, together with their proposed mech - anism of action, make them useful for type 2 diabetes mellitus, especially when used in combination therapy.
    [Show full text]
  • Indiscriminative Effects of Repaglinide and Other Specific Modulators of Transmembrane KATP-Channel Gating Properties Upon Ischa
    Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2003; 6 (Issue 1-4), 81-85 Indiscriminative Effects of Repaglinide and Other Specific Modulators of Transmembrane KATP-Channel Gating Properties upon Ischaemic/Hypoxic Bovine Coronary Artery Smooth Muscle Relaxation Gasser R, Esche G, Gasser S, Holzmann S, Köppel H Moosbrugger B, Salzer M Homepage: www.kup.at/jcbc Online Data Base Search for Authors and Keywords Indexed in Chemical Abstracts EMBASE/Excerpta Medica Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria ORIGINAL PAPERS, BASIC CARDIOLOGY Repaglinide and Coronary Dilation J Clin Basic Cardiol 2003; 6: 81 Indiscriminative Effects of Repaglinide and Other Specific Modulators of Transmembrane KATP-Channel Gating Properties upon Ischaemic/Hypoxic Bovine Coronary Artery Smooth Muscle Relaxation R. Gasser1, H. Köppel2, B. Moosbrugger1, G. Esche1, M. Salzer1, S. Gasser1, S. Holzmann3 The opening of KATP channels both in myocardium and vascular smooth muscle constitutes an important mechanism in the regulation of myocardial metabolism and perfusion, in particular, during hypoxia and ischaemia. In coronary smooth muscle, KATP channel opening invariably leads to vasodilation and hence to improved myocardial perfusion. Blockade of these chan- nels may disturb this pivotal response. We compare the effects of glibenclamide with two new sulfonylureas on coronary artery dilation secondary to hypoxia and simulated ischaemia. We use bovine coronary arteries in a modified Tyrode solution (equili- brated with 95 % O2 and 5 % CO2 at 37 °C at a constant pH of 7.4). The solution contained the following solutes (in mM): NaCl 112.8, KCl 26.8, CaCl2 1.36, MgSO4 1.16, NaHCO3 11.9, glucose 10.1.
    [Show full text]
  • ACCEPTABLE COMBINATIONS of DIABETES MEDICATIONS (Updated 01/27/2021)
    ACCEPTABLE COMBINATIONS OF DIABETES MEDICATIONS (Updated 01/27/2021) The chart on the following page outlines acceptable combinations of medications for treatment of diabetes. Please note: • Initial certification of all applicants with diabetes mellitus (DM) requires FAA decision; • Use no more than one medication from each group (A-F); • Fixed-dose combination medications - count each component as an individual medication. (e.g., Avandamet [rosiglitazone + metformin] is considered 2-drug components); • Up to 3 medications total are considered acceptable for routine treatment according to generally accepted standards of care for diabetes (American Diabetes Association, American Association of Clinical Endocrinologists); • For applicants receiving complex care (e.g., 4-drug therapy), refer the case to AMCD; • For applicants on AASI for diabetes mellitus, follow the AASI; • Consult with FAA for any medications not on listed on the chart; • Observation times: When initiating NEW diabetes therapy using monotherapy or combination medications: Adding Medication Observation Time Group A ONLY 14 days Group B-D 30 days Group E1 60 days When ADDING a new medication to an ESTABLISHED TREATMENT regimen: Current Medication Adding Medication Observation Time on Group A-D + new Group A-D 14 days on Group E1 + new Group A-D 30 days on Group A-D + new Group E1 60 days Note: If transitioning between injectable GLP-1 RA and oral GLP-1 RA formulation = 72 hours When initiating NEW or ADDING therapy for any regimen (new or established therapy): Adding Medication Observation Time Group F (SGLT2 inhibitors) 90 days Group E2 (insulin): • For agency ATCSs (non-CGM or CGM protocol) 90 days • For Pilots / Part 67 applicants, class 3 non-CGM 90 days protocol only: 180 days • For Pilots / Part 67 applicants, any class CGM protocol: ACCEPTABLE COMBINATIONS OF DIABETES MEDICATIONS (Updated 01/27/2021) Biguanides A -metformin (e.g.
    [Show full text]
  • Pre-Surgery Diabetes Medications
    *6675* 6675 The Day Before and Day of Surgery or Procedure A Guide to Diabetes Medications 1. Find the prescribed medication on this page and follow those instructions unless the diabetes provider advises you differently. 2. Check blood sugar before meals and bedtime for at least 2 days prior to procedure or surgery (if checked more often, continue routine). Call the doctor if the blood sugar is higher than 150 twice. 3. Combination pills are not listed below. If a pill combines two medications, and one of the medications is listed as “Do not take” or “stop”, do not use the combination pill. 4. If pregnant, follow instructions of the diabetes provider. ON DAY BEFORE SURGERY or PROCEDURE ON DAY OF SURGERY or PROCEDURE You may take the following medications Do not take these Medications in the morning Actos (Pioglitazone) Amaryl (Glimiperide) Amaryl (Glimiperide) Glucophage, and others (Metformin) - Check with Avandia (Rosiglitazone) your doctor when to restart Byetta (Exenatide) Glucotrol (Glipizide) Glucophage, and others (Metformin) Micronase, Diabeta, and others (Glyburide) With normal kidney function – Take as usual **************************************** Glucophage, and others (Metformin) - If Do not take the medications below in the unknown or decreased kidney function – Stop morning, but may resume after surgery or 48 hours before surgery/procedure procedure Glucotrol (Glipizide) Avandia (Rosiglitazone) Januvia (Sitagliptin) Actos (Pioglitazone) Micronase, Diabeta, and others (Glyburide) Byetta (Exenatide) Prandin (Repaglinide) Januvia (Sitagliptin) Starlix (Nateglinide) Prandin (Repaglinide) Symlin (Pramlintide) Symlin (Pramlintide) Starlix (Nateglinide) INSULIN ON DAY/NIGHT BEFORE SURGERY INSULIN in AM OF SURGERY or PROCEDURE or PROCEDURE Type 1 diabetes mellitus (T1DM) may need a Type 1 diabetes mellitus (T1DM) may need a decreased decreased dose of insulin at bedtime.
    [Show full text]
  • PRANDIN (Repaglinide) Tablets Are Supplied As Unscored, Biconvex Tablets Available in 0.5 Mg (White), 1 Mg (Yellow) and 2 Mg (Peach) Strengths
    PRANDIN® (repaglinide) Tablets (0.5, 1, and 2 mg) Rx only DESCRIPTION PRANDIN® (repaglinide) is an oral blood glucose-lowering drug of the meglitinide class used in the management of type 2 diabetes mellitus (also known as non-insulin dependent diabetes mellitus or NIDDM). Repaglinide, S(+)2-ethoxy-4(2((3-methyl-1-(2-(1-piperidinyl) phenyl)­ butyl) amino)-2-oxoethyl) benzoic acid, is chemically unrelated to the oral sulfonylurea insulin secretagogues. The structural formula is as shown below: CH3 O OH 3CH O N O H N CH3 Repaglinide is a white to off-white powder with molecular formula C27 H36 N2 O4 and a molecular weight of 452.6. PRANDIN tablets contain 0.5 mg, 1 mg, or 2 mg of repaglinide. In addition each tablet contains the following inactive ingredients: calcium hydrogen phosphate (anhydrous), microcrystalline cellulose, maize starch, polacrilin potassium, povidone, glycerol (85%), magnesium stearate, meglumine, and poloxamer. The 1 mg and 2 mg tablets contain iron oxides (yellow and red, respectively) as coloring agents. CLINICAL PHARMACOLOGY Mechanism of Action Repaglinide lowers blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent upon functioning beta (ß) cells in the pancreatic islets. Insulin release is glucose-dependent and diminishes at low glucose concentrations. Repaglinide closes ATP-dependent potassium channels in the ß-cell membrane by binding at characterizable sites. This potassium channel blockade depolarizes the ß-cell, which leads to an opening of calcium channels. The resulting increased calcium influx induces insulin secretion. The ion channel mechanism is highly tissue selective with low affinity for heart and skeletal muscle.
    [Show full text]
  • New Drug Evaluation Monograph Template
    Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Month/Year of Review: April 2012 Date of Last Review: June 2009 PDL Classes: DPP4 Inhibitors Source Document: DERP Report (June 2009) GLP-1 agonists and analogs Oral Hypoglycemics Thiazolidinediones Current Preferred Agents: Current Non-Preferred Agents: Dipeptidyl peptidase (DPP4 ) Inhibitors Oral hypoglycemics GLP-1 Analogs Sitagliptan/metformin (Janumet) Glyburide micronized Exenatide (Byetta) Sitagliptan (Januvia) Chlorpropamide Liraglutide (Victoza) Tolbutamide Glucagon-like peptide (GLP)-1 Analogs Repaglinide (Prandin) Combination Products Pramlintide (Symlinpen 60 and 120) Nateglinide (Starlix) Rosiglitazone/Glimepiride (Avandaryl) Tolazamide Pioglitazone/Glimepiride (Duetact) Thiazolidinediones (TZD’s)_ Pioglitazone/metformin (Actoplus Met) Pioglitazone (Actos) Thiazolidinediones Rosiglitazone/metformin (Avandamet) Rosiglitazone (Avandia) Glyburide/metformin Oral hypoglycemics Glipizide/metformin Glimepiride DPP4 Inhibitors Repaglinide/metformin (Prandimet) Glipizide Linagliptan (Tradjenta) Saxagliptan /metformin (Kombiglyze XR) Glyburide Saxagliptan (Onglyza) Linagliptan/metformin (Jentadueto) Metformin Sitagliptan/metformin (Janumet XR) Metformin ER Previous Recommendations: Oral Hypoglycemics 1. There is no clinically significant difference between any of the agents in these two drug classes (oral sulfonylureas and non-sulfonylurea secretagogues) in their ability to lower
    [Show full text]